ATE225652T1 - Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts - Google Patents

Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts

Info

Publication number
ATE225652T1
ATE225652T1 AT96917640T AT96917640T ATE225652T1 AT E225652 T1 ATE225652 T1 AT E225652T1 AT 96917640 T AT96917640 T AT 96917640T AT 96917640 T AT96917640 T AT 96917640T AT E225652 T1 ATE225652 T1 AT E225652T1
Authority
AT
Austria
Prior art keywords
fgfr3
bone
progenitor cells
skeletal progenitor
marker
Prior art date
Application number
AT96917640T
Other languages
English (en)
Inventor
Avner Yayon
Zvi Nevo
Original Assignee
Yeda Res & Dev
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Univ Ramot filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE225652T1 publication Critical patent/ATE225652T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96917640T 1995-06-12 1996-06-12 Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts ATE225652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13795P 1995-06-12 1995-06-12
PCT/IL1996/000010 WO1996041620A1 (en) 1995-06-12 1996-06-12 Fgfr3 as a marker for mesenchymal skeletal progenitor cells

Publications (1)

Publication Number Publication Date
ATE225652T1 true ATE225652T1 (de) 2002-10-15

Family

ID=21690089

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96917641T ATE213590T1 (de) 1995-06-12 1996-06-12 Fgf9 als spezifischer ligand für fgfr3
AT96917640T ATE225652T1 (de) 1995-06-12 1996-06-12 Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96917641T ATE213590T1 (de) 1995-06-12 1996-06-12 Fgf9 als spezifischer ligand für fgfr3

Country Status (12)

Country Link
US (2) US6447783B1 (de)
EP (3) EP0836380B1 (de)
JP (3) JP3673281B2 (de)
CN (1) CN1195982A (de)
AT (2) ATE213590T1 (de)
AU (2) AU721773B2 (de)
CA (2) CA2224229A1 (de)
DE (2) DE69619526T2 (de)
DK (2) DK0833620T3 (de)
ES (2) ES2173289T3 (de)
IL (2) IL122473A (de)
WO (2) WO1996041523A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468075B2 (en) 2001-05-25 2008-12-23 Conformis, Inc. Methods and compositions for articular repair
US7618451B2 (en) 2001-05-25 2009-11-17 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty
US8480754B2 (en) 2001-05-25 2013-07-09 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US8545569B2 (en) 2001-05-25 2013-10-01 Conformis, Inc. Patient selectable knee arthroplasty devices
US8882847B2 (en) 2001-05-25 2014-11-11 Conformis, Inc. Patient selectable knee joint arthroplasty devices
US8771365B2 (en) 2009-02-25 2014-07-08 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs, and related tools
US8735773B2 (en) 2007-02-14 2014-05-27 Conformis, Inc. Implant device and method for manufacture
US8556983B2 (en) 2001-05-25 2013-10-15 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs and related tools
US9603711B2 (en) 2001-05-25 2017-03-28 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US8083745B2 (en) 2001-05-25 2011-12-27 Conformis, Inc. Surgical tools for arthroplasty
US7534263B2 (en) 2001-05-25 2009-05-19 Conformis, Inc. Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty
US6136040A (en) * 1998-03-05 2000-10-24 Washington University Animal model with disrupted FGF-9 gene
US7239908B1 (en) 1998-09-14 2007-07-03 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
AU772012B2 (en) 1998-09-14 2004-04-08 Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and preventing damage
US20020058036A1 (en) * 1999-07-27 2002-05-16 Michael Jeffers Novel fibroblast growth factor and nucleic acids encoding same
DE60016288T2 (de) 1999-10-06 2005-12-01 Tigenix N.V. Isolierung von vorläuferzellen und deren verwendung zum wiederaufbau von bindegewebe
AU7764200A (en) 1999-10-06 2001-05-10 Tigenix N.V. In vivo assay and molecular markers for testing the phenotypic stability of cellpopulations, and selecting cell populations for autologous transplantation
US7482114B2 (en) 1999-10-06 2009-01-27 Tigenix N.V. In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation
EP1255771A4 (de) * 2000-02-14 2004-09-29 Smithkline Beecham Corp Neue zusammensetzungen
WO2001068854A2 (en) * 2000-03-13 2001-09-20 Amgen, Inc. Fibroblast growth factor-like molecules and uses thereof
WO2002022013A1 (en) 2000-09-14 2002-03-21 The Board Of Trustees Of The Leland Stanford Junior University Assessing condition of a joint and cartilage loss
AU2001290888B8 (en) 2000-09-14 2007-07-26 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
JP2004517638A (ja) * 2001-02-02 2004-06-17 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 機能的核酸の同定方法
US9308091B2 (en) 2001-05-25 2016-04-12 Conformis, Inc. Devices and methods for treatment of facet and other joints
CN100502808C (zh) 2001-05-25 2009-06-24 肯弗默斯股份有限公司 用于关节表面再造的组合物
US8439926B2 (en) 2001-05-25 2013-05-14 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003076467A1 (en) * 2002-03-14 2003-09-18 Yeda Research And Development Co. Ltd. Compositions and methods for inducing and regulating bone formation
AU2003265057A1 (en) * 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
WO2004032806A1 (en) 2002-10-07 2004-04-22 Conformis, Inc. Minimally invasive joint implant with 3-dimensional geometry matching the articular surfaces
CN1780594A (zh) 2002-11-07 2006-05-31 康复米斯公司 用于确定半月板的大小和形状以及设计治疗的方法
AU2011211453B2 (en) * 2004-06-21 2015-01-15 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
TR201900968T4 (tr) * 2004-09-24 2019-02-21 Mesoblast Inc Multipotansiyel genleşmiş mezenkimal prekürsör hücre soyu (memp) ve bunların kullanımı.
US7391676B2 (en) * 2004-12-22 2008-06-24 Asml Netherlands B.V. Ultrasonic distance sensors
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US20070049739A1 (en) * 2005-08-30 2007-03-01 Biomet Manufacturing Corp. Method and system for extracting blood-derived growth factors
US8623026B2 (en) 2006-02-06 2014-01-07 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief
EP2671521A3 (de) 2006-02-06 2013-12-25 ConforMIS, Inc. Vom Patienten auswählbare Gelenkarthroplastie-Vorrichtungen und chirurgische Instrumente
CN101657536B (zh) * 2007-01-23 2016-06-01 公立大学法人横浜市立大学 软骨细胞制备方法
EP2591756A1 (de) 2007-02-14 2013-05-15 Conformis, Inc. Implantat und Herstellungsverfahren
WO2008157412A2 (en) 2007-06-13 2008-12-24 Conformis, Inc. Surgical cutting guide
US8682052B2 (en) 2008-03-05 2014-03-25 Conformis, Inc. Implants for altering wear patterns of articular surfaces
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US12383287B2 (en) 2009-02-24 2025-08-12 Microport Orthopedics Holdings, Inc. Systems and methods for installing an orthopedic implant
US9017334B2 (en) 2009-02-24 2015-04-28 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
US8808297B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US8808303B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
WO2010099231A2 (en) 2009-02-24 2010-09-02 Conformis, Inc. Automated systems for manufacturing patient-specific orthopedic implants and instrumentation
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
CN102448394B (zh) 2009-04-16 2015-07-22 康复米斯公司 用于韧带修复的患者专属关节成形术装置
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
AU2010327987B2 (en) 2009-12-11 2015-04-02 Conformis, Inc. Patient-specific and patient-engineered orthopedic implants
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
WO2012112701A2 (en) 2011-02-15 2012-08-23 Conformis, Inc. Patent-adapted and improved articular implants, designs, surgical procedures and related guide tools
US9486226B2 (en) 2012-04-18 2016-11-08 Conformis, Inc. Tibial guides, tools, and techniques for resecting the tibial plateau
US9675471B2 (en) 2012-06-11 2017-06-13 Conformis, Inc. Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
US20150216860A1 (en) 2013-03-10 2015-08-06 National University Corporation Nagoya University Therapeutic agent for systemic bone disease and use thereof
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
AU2020283377B2 (en) 2019-05-29 2022-08-04 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle
JP2020015733A (ja) * 2019-08-19 2020-01-30 アンセルムＩｎｓｅｒｍ 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
IT201900025126A1 (it) * 2019-12-20 2021-06-20 Sildeha Swiss S A Uso di derivati dell’acido ialuronico nella rigenerazione dei tessuti ossei e cartilaginei
WO2021146015A1 (en) 2020-01-17 2021-07-22 Wright Medical Technology, Inc. Guidance tools, systems, and methods
WO2022182430A1 (en) 2021-02-24 2022-09-01 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle
US12582421B2 (en) 2022-05-13 2026-03-24 Wright Medical Technology, Inc. Intraoperative adjustable guides, systems, and methods
CN116162589B (zh) * 2022-12-30 2025-10-03 西北工业大学 干细胞及其制备方法和应用、及标记组合物及其应用
US12569355B2 (en) 2023-08-31 2026-03-10 Wright Medical Technology, Inc. Systems and methods for total ankle arthroplasty

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5226914A (en) * 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5270197A (en) * 1990-12-20 1993-12-14 The Children's Medical Center Corporation Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor
JP3385040B2 (ja) * 1991-02-14 2003-03-10 武田薬品工業株式会社 グリア活性化因子およびその製造法
EP0608546A3 (en) * 1992-12-22 1995-09-27 Takeda Chemical Industries Ltd Glia activating factor (gaf), antibodies against it and their uses.
AU6446194A (en) * 1993-03-17 1994-10-11 Whittier Institute For Diabetes And Endocrinology, The Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof

Also Published As

Publication number Publication date
WO1996041523A1 (en) 1996-12-27
EP0833620B1 (de) 2002-10-09
EP1342476A3 (de) 2003-09-17
ES2173289T3 (es) 2002-10-16
CA2223701C (en) 2010-02-16
AU715996B2 (en) 2000-02-17
US20020193309A1 (en) 2002-12-19
CN1195982A (zh) 1998-10-14
IL122472A (en) 2003-11-23
EP0836380A4 (de) 1999-03-31
EP0836380B1 (de) 2002-02-27
DK0833620T3 (da) 2003-01-13
JPH11508358A (ja) 1999-07-21
EP0833620A4 (de) 1998-05-06
EP1342476A2 (de) 2003-09-10
AU6014596A (en) 1997-01-09
WO1996041620A1 (en) 1996-12-27
ATE213590T1 (de) 2002-03-15
JP3673281B2 (ja) 2005-07-20
IL122472A0 (en) 1998-06-15
CA2224229A1 (en) 1996-12-27
JPH11507828A (ja) 1999-07-13
IL122473A0 (en) 1998-06-15
JP2004305221A (ja) 2004-11-04
DK0836380T3 (da) 2002-04-22
AU6014496A (en) 1997-01-09
EP0836380A1 (de) 1998-04-22
DE69619526T2 (de) 2002-10-31
DE69624239D1 (de) 2002-11-14
US6447783B1 (en) 2002-09-10
ES2183957T3 (es) 2003-04-01
AU721773B2 (en) 2000-07-13
EP0833620A1 (de) 1998-04-08
CA2223701A1 (en) 1996-12-27
DE69624239T2 (de) 2003-07-10
IL122473A (en) 2003-11-23
DE69619526D1 (de) 2002-04-04

Similar Documents

Publication Publication Date Title
DE69624239D1 (de) Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
YU7797A (sh) Kombinovana terapija za osteoporozu
DE69329903D1 (de) Bioabbaubare polymere zur zelltransplantation
AR009742A1 (es) Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su preparacion
NZ225344A (en) 3-demethylmevalonic acid derivatives and lactones and pharmaceutical compositions; intermediates for the preparation thereof
DE69435198D1 (de) "hedgehog-like" proteine von wirbeltieren, die embryonale strukturen induzieren
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
ATE265863T1 (de) Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
PT1053256E (pt) Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
NZ223549A (en) Macromolecular antitumour compositions containing platinum
GR890100846A (el) Μεθοδος μετατροπης κυτταρικης διαφοροποιησης και λειτουργιας καισυνθεσεις της.
TR199901433T2 (xx) Pirolo$3,4-D] pirimidinon t�revleri ve bunlar�n ila� olarak kullan�mlar�.
IL141877A0 (en) Pharmaceutical compositions containing alpha4 integrin antagonists
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
ATE222122T1 (de) Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
CA2069638A1 (en) Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
EP0888345A4 (de) Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation
DE69737455D1 (de) Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben
Hernandez-Vidal et al. Immunolocalization of cathepsin B in equinedyschondroplastic articular cartilage
Enomoto et al. Demonstration of receptors for parathyroid hormone on cultured rabbit costal chondrocytes
ATE17738T1 (de) Mitogene aus leukozyten und entzuendeten geweben: natuerliche leukopoietische proteine fuer die spezifische induktion der vermehrung und der differenzierung von leukozyten; verfahren zu ihrer biotechnischen herstellung und pharmazeutische zusammensetzungen.
TR200000444T2 (tr) 3-Aril-süksinamido-hidroksamik asitler, üretim yöntemleri ve bu maddeleri içeren farmasötik terkipler.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0833620

Country of ref document: EP

REN Ceased due to non-payment of the annual fee